| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1734-1140(13)71496-8 |
| P698 | PubMed publication ID | 24399734 |
| P2093 | author name string | Tester F Ashavaid | |
| Farah Jijina | |||
| Chandrashekhar K Ponde | |||
| Rajesh M Rajani | |||
| Sripriya Natarajan | |||
| Pradnya P Dhairyawan | |||
| Roopkumar Gursahani | |||
| P2860 | cites work | Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians | Q43708731 |
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population | Q46537848 | ||
| VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. | Q46548969 | ||
| Optimization of warfarin dose by population-specific pharmacogenomic algorithm. | Q51598231 | ||
| CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. | Q54684440 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes | Q80352091 | ||
| Warfarin pharmacogenetics | Q81887452 | ||
| A simple salting out procedure for extracting DNA from human nucleated cells | Q27861086 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Long-term management of patients after venous thromboembolism | Q28279920 | ||
| Managing oral anticoagulant therapy | Q30649541 | ||
| Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range | Q31828961 | ||
| American Heart Association/American College of Cardiology Foundation guide to warfarin therapy | Q34196283 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| The future prospects of pharmacogenetics in oral anticoagulation therapy | Q34530230 | ||
| CYP4F2 genetic variant alters required warfarin dose | Q34746151 | ||
| Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy | Q35092508 | ||
| Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin | Q35204081 | ||
| Evaluation of genetic factors for warfarin dose prediction | Q35758421 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| Warfarin dosing and the promise of pharmacogenomics. | Q37239112 | ||
| Warfarin sensitivity genotyping: a review of the literature and summary of patient experience | Q37454438 | ||
| Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses | Q40817018 | ||
| Influence of GGCX genotype on warfarin dose requirements in Chinese patients | Q42769189 | ||
| Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients | Q43118235 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | India | Q668 |
| (RS)-warfarin | Q407431 | ||
| P304 | page(s) | 1375-1382 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Pharmacological Reports | Q15766499 |
| P1476 | title | Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients | |
| P478 | volume | 65 |
| Q40000464 | A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts |
| Q90663188 | Antagonists of Vitamin K-Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives |
| Q39022910 | DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation |
| Q54935902 | Disease burden and the role of pharmacogenomics in African populations. |
| Q61449022 | Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy |
| Q90859680 | Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism |
| Q55008394 | N-of-1 trials in the clinical care of patients in developing countries: a systematic review. |
| Q33782314 | The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population. |
| Q39066100 | Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. |
Search more.